Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab ± chemotherapy as adjuvant therapy after resection of locally advanced esophageal squamous cell carcinoma
ChiCTR2600118439Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: 2-year disease-free survival rate. Started Feb 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600118439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118439.